

Preliminary Programme

Dubrovnik, Croatia
1-3 October 2025

Wednesday, 1 October 2025

16:00 – 18:00 Scientific Business Meeting

Thursday, 2 October 2025

08:30 – 08:40 Welcome from the organisers

08:40 – 10:00 Session I: Patient journey through allogeneic stem cell transplantation

08:40 – 09:00 Keynote lecture on acute GVHD

Mohamad Mohty (FR)

09:00 – 10:00 Panel discussion

We will interactively go through patient cases. Recognition of complications and their treatment will be covered. Pre-transplant assessment of co-morbidities and risk factors will also be discussed. Finally, we will discuss practical tips for patients recovering from HSCT, supporting patients in return to society, work, family, and their rehabilitation.

Eolia Brissot (FR)
Radovan Vrhovac (HR)
Robert Tićac (HR)

Case presentation by Ajna Džanić (HR): Comprehensive nursing care of a Patient with gastrointestinal tract GVHD and associated complications.

10:00 – 10:30 Industry Symposium by Therakos

10:30 – 10:50 Coffee break

10:50 – 12:10 Session II: Prevention of allo-transplant complications

10:50 – 11:10 Keynote lecture

Nicolaus Kröger (DE)

11:10 – 12:10 Panel discussion

Some complications despite major advancements in recent years still pose a significant risk of non-relapse mortality. Currently, we have different transplantation technologies to reduce the risk of GVHD, graft failure and infectious complications. We will discuss existing strategies to improve patients' outcomes and prevent post-transplant complications – as choice of donor, prevention of GVHD and other aspects of transplantation.

Ivan Moiseev (RU)
Nadira Duraković (HR)
Dženana Džaferagić (HR)

Case presentation by Lara Divjak (HR): Mitigating GvHD Risk After Checkpoint Inhibitor Therapy: A Case of PYCy-Based Prophylaxis in CAEBV-Associated HLH.

12:10 – 12:30 Industry Symposium by Takeda

12:30 – 13:30 Lunch break

13:30 – 14:50 Session III: Patient journey through early complications

13:30 – 13:50 Keynote on TMA

Rafael Duarte (ES)

13:50 – 14:50 Panel discussion

How to recognize and treat infectious and non-infectious complications in the early phase after alloSCT will be presented in an interactive fashion. We will discuss management of VOD/SOS as well as TMA with the participants based on patient cases. We will also focus on organ toxicities, including renal, central nervous and liver manifestations.

Grzegorz Basak (PL)
Lana Desnica (HR)
Job Rexal Perez Gaddi (HR)

Thursday, 2 October 2025 - continued

14:50 – 15:35	Industry Symposium by Alexion/AstraZeneca	
15:35 – 16:05	Coffee Break	
16:05 – 17:25	Session IV: Patient journey through GVHD	
16:05 – 16:25	Keynote lecture (cGVHD section)	Steven Pavletic (US)
16:25 – 17:25	Panel discussion We will discuss management of GVHD with the participants based on patient cases. Recognition of complications and their treatment will be discussed in an interactive fashion. Attendees will improve their skills in diagnosis and grading of GVHD as well as in therapy of acute and chronic steroid-refractory GVHD. In addition, we will give practical tips caring for a patient with GvHD, e.g. on eye, mouth and skin care.	Olaf Penack (DE) Dražen Pulanić (HR) Vedrana Turković (HR) Lucija Jurišić (HR)
17:25 – 18:45	Session V: Patient journey through late effects	
17:25 – 17:45	Keynote on Patient reported outcomes	Hélène Schoemans (BE)
17:45 – 18:45	Panel discussion We will talk about clinical presentation of late effects based on individual patient cases. Attendees will learn how to better detect and manage different late effects including cardiovascular, renal, endocrine, neurological complications, as well as secondary cancer and gender-specific late effects. The basics of assessing symptoms and late effects will be explained, and the use of up-to-date tools to use patient reported outcomes will be discussed.	Lars Klingen Gjørde (DK) Zinaida Perić (HR) Matea Meden (HR)

Preliminary Programme

Dubrovnik, Croatia
1-3 October 2025

Friday, 3 October 2025

09:00 – 10:45

Session VI: Patient journey through CAR T-cell therapy

09:00 – 09:30

Keynote lecture

Reuben Benjamin (UK)

09:30 – 10:45

Panel discussion

Using patient cases, we will discuss pre-CART assessment of co-morbidities and risk factors. We will talk about bridging therapy, lymphodepletion, risk for complications and follow up. In an interactive fashion attendees will learn how to manage early and late complications after CAR-T therapy
Case presentation by Katarzyna Pruszczyk-Matusiak (PL): Multiple early complications of CAR-T therapy in one patient.

Charlotte Graham (IT)
Daniele Avenoso (IT)
Orla Stewart (UK)

10:45 – 11:00

Coffee break

11:00 – 12:45

Session VII: Patient journey through CAR T-cell therapy complications

11:00 – 11:30

Keynote lecture

Anna Sureda (ES)

11:30 – 12:45

Panel discussion

We will focus on improving skills in diagnosis and grading of CRS and ICANS as well as cytopenias and infections. We will go through cases with The participants and discuss the prevention, diagnosis, and management of these complications. We will also assess more rare complications as neurological, HLH etc.
Case presentation by Tajana Grenko Malnar (HR): CAR-T Therapy in Primary CNS Lymphoma: Role of the CAR-HEMATOTOX Score in Predicting and Mitigating Cytopenias and Infections.

Alberto Mussetti (ES)
Paul Ferguson (UK)
V́ctor Noriega (ES)

12:45 – 13:00

Closing remarks and farewell